Pfizer Inc
Trump tells drugmakers to ‘justify the success’ of Covid meds after FDA limits vaccine approval
U.S. President Donald Trump in the Cabinet Room of the White House on Aug. 26, 2025 in Washington, D.C. Chip Somodevilla | Getty Images President Donald Trump on Monday called on pharmaceutical companies to “justify the success” of their Covid drugs days after the Food and Drug Administration set new limits on who can receive […]
Read More
The vaccine and public health debate at the center of CDC upheaval, explained
The exterior of the Center for Disease Control and Prevention (CDC) main campus in Atlanta, Georgia, U.S., Aug. 27, 2025. Alyssa Pointer | Reuters The Centers for Disease Control and Prevention is facing a leadership upheaval — and at the center of the shakeup is concern about the agency’s approach to vaccines and U.S. public […]
Read More
FDA approves new Covid shots with limits on who can get them, as RFK Jr. changes vaccine precedents
Pfizer’s Covid vaccine Comirnaty, seen at a CVS Pharmacy in Eagle Rock, California, Sept. 14, 2023. Irfan Khan | Los Angeles Times | Getty Images The Food and Drug Administration on Wednesday approved the latest round of Covid vaccines in the U.S., but set new limits on who can get them. The agency ended its […]
Read More
A world on weight loss drugs: How GLP-1s are reshaping the economy
Eternalcreative | Istock | Getty Images Miracle drugs, obesity treatments and skinny jabs. Call them what you will, few drugs have had a more transformative effect on Wall Street and waistlines over recent decades than GLP-1s. Familiarly known under the brand names Wegovy and Zepbound, Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medication used to […]
Read More
Eli Lilly’s obesity pill remains a viable rival to Novo’s oral Wegovy despite data that underwhelmed investors
A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Eli Lilly‘s stock is still recovering after the drugmaker released trial data earlier this month on its closely watched obesity pill that underwhelmed Wall Street. In a key late-stage trial, […]
Read More
Viking Therapeutics shares fall more than 30% on disappointing obesity pill trial data
Shares of Viking Therapeutics fell more than 30% in premarket trading Tuesday after the company released mid-stage trial data on its obesity pill that disappointed investors. The results could be a blow to Viking, which was once seen as a hot M&A target as pharmaceutical companies scramble to join the booming market for obesity and […]
Read More
FDA may pull authorization of Pfizer’s Covid vaccine for children under 5
A nurse prepares doses of the Pfizer vaccine during a COVID-19 vaccination event at Josephine’s Southern Cooking in Chatham, Illinois, Dec. 30, 2021. Brian Cassella | Tribune News Service | Getty Images The Food and Drug Administration is weighing revoking its authorization of Pfizer‘s Covid-19 vaccine for healthy children under the age of 5, the […]
Read More
Healthy Returns: Medicare, Medicaid will reportedly pilot covering obesity drugs – a potential win for drugmakers
A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, made by Novo Nordisk. Hollie Adams | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. For […]
Read More
Stocks making the biggest moves midday: Pfizer, Palantir, Coinbase, Staar Surgical and more
Check out some of the companies making the biggest moves midday: Staar Surgical — The implantable eye lens maker ripped 45% higher after agreeing to be bought by Alcon for $28 per share in cash, valuing Staar at about $1.5 billion. The deal is expected to close in the next six to 12 months. DigitalOcean […]
Read More
Stocks making the biggest premarket moves: Pfizer, Eaton, Palantir, Yum and more
Check out the companies making the biggest moves in premarket trading: Palantir Technologies — The defense technology stock jumped 6.8% after quarterly revenue exceeded $1 billion for the first time and it raised full-year guidance. Palantir now anticipates revenue for the year to range between $4.142 billion and $4.150 billion, up from prior guidance of […]
Read More